- Pemetrexed-carbo plus bevacizumab and atezolizumab was effective in EGFR mutated lung cancer.
- Median PFS of 9.4 months, 1 year OS 72.5% in this heavily pretreated population were remarkable.
- Having similar efficacy, this regimen gave less toxicity compared with IMPower150 regimen.
- QoL was well preserved in patients which used pemetrexed as chemotherapy backbone.
- Post-trial rechallenge with EGFR TKI was effective with median PFS 4–6 months.